In last trading session, Processa Pharmaceuticals Inc (NASDAQ:PCSA) saw 0.5 million shares changing hands with its beta currently measuring 0.19. Company’s recent per share price level of $0.43 trading at $0.01 or 3.34% at ring of the bell on the day assigns it a market valuation of $10.59M. That closing price of PCSA’s stock is at a discount of -420.93% from its 52-week high price of $2.24 and is indicating a premium of 58.14% from its 52-week low price of $0.18. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.54 million shares which gives us an average trading volume of 2.04 million if we extend that period to 3-months.

For Processa Pharmaceuticals Inc (PCSA), analysts’ consensus is at an average recommendation of a Hold while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.1 in the current quarter.

Processa Pharmaceuticals Inc (NASDAQ:PCSA) trade information

Upright in the green during last session for gaining 3.34%, in the last five days PCSA remained trading in the green while hitting it’s week-highest on Friday, 11/17/23 when the stock touched $0.43 price level, adding 4.87% to its value on the day. Processa Pharmaceuticals Inc’s shares saw a change of -60.92% in year-to-date performance and have moved 37.44% in past 5-day. Processa Pharmaceuticals Inc (NASDAQ:PCSA) showed a performance of -20.39% in past 30-days. Number of shares sold short was 0.21 million shares which calculate 0.04 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $1.00 to the stock, which implies a rise of 57.0% to its current value. Analysts have been projecting $1.00 as a low price target for the stock while placing it at a high target of $1.00. It follows that stock’s current price would drop -132.56% in reaching the projected high whereas dropping to the targeted low would mean a loss of -132.56% for stock’s current value.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -32.30% during past 5 years. In 2023, company’s earnings growth rate is likely to be around 75.88% while estimates for its earnings growth in next 5 years are of 15.00%.

PCSA Dividends

Processa Pharmaceuticals Inc is more likely to be releasing its next quarterly report on November 13 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Processa Pharmaceuticals Inc (NASDAQ:PCSA)’s Major holders

Insiders are in possession of 16.23% of company’s total shares while institution are holding 6.53 percent of that, with stock having share float percentage of 7.80%. Investors also watch the number of corporate investors in a company very closely, which is 6.53% institutions for Processa Pharmaceuticals Inc that are currently holding shares of the company. Walleye Capital LLC is the top institutional holder at PCSA for having 0.42 million shares of worth $0.18 million. And as of Sep 29, 2023, it was holding 7.60% of the company’s outstanding shares.

The second largest institutional holder is Vanguard Group Inc, which was holding about 0.34 million shares on Sep 29, 2023. The number of shares represents firm’s hold over 6.24% of outstanding shares, having a total worth of $0.15 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 0.3 million shares of worth $0.13 million or 5.43% of the total outstanding shares. The later fund manager was in possession of 46013.0 shares on Jun 29, 2023, making its stake of worth around $19780.0 in the company or a holder of 0.83% of company’s stock.